ImmuPharma enter into agreements with two specialist US healthcare investors for a total investment of up to $6.30 million

ImmuPharma PLC (LON:IMM, the specialist drug discovery and development company, has announced that it has entered into agreements with two specialist US healthcare investors for a total investment of up to $6.30 million (£4.94 million) comprising an issue of unsecured convertible securities and associated options.

Highlights

·    ImmuPharma is to issue $3 million (£2.35 million) in face value of Securities to two US specialist healthcare investors, L1 Capital Global Opportunities Master Fund and Lind Global Macro Fund LP, managed by The Lind Partners, LLC (“the Investors”) with a maturity period of 18 months.

·    At any time, during the maturity period, the Investors may convert their Securities (in whole or in part) to 13,086,619 ordinary shares in the Company, in aggregate, at a price of 17.96p (“Conversion Price”) which is equivalent to 120% of the Volume Weighted Average Price (“VWAP”) of the ordinary shares for 09 June 2020.

·    During the maturity period, the Company may require the investors to convert their securities to ordinary shares, if the VWAP on each of at least 20 consecutive trading days shall be equal to or have exceeded 35.92p (200% of the Conversion Price).

·    Should any securities remain unconverted on 10 December 2021  the Company will repurchase, from the Investors, the outstanding face value of the unconverted Securities.

·    In addition, the Investors have been granted 15,703,942 Options in the Company, which may be exercised at any time up to 3 years,  with an exercise price the same as the Conversion Price, which, if all exercised, would amount to $3.60 million (£2.82 million).

·    The initial net proceeds of the Securities (after subscription and expenses) received by the Company of $2.39 million (£1.87 million) and any additional funds received of up to $3.60 million (£2.82 million), following exercise of the Options, will be used primarily to fund:

  • Continued expansion of the Company’s R&D programmes; and
  • General working capital.

Commenting, ImmuPharma’s Chairman, Tim McCarthy, said:

“We are delighted to welcome L1 Capital Global Opportunities Master Fund and Lind Global Macro Fund LP as new investors into ImmuPharma. This is the first significant investment from specialist US healthcare funds and illustrates the attention we are now receiving from knowledgeable global investors. It particularly exemplifies the strengthened investment thesis of ImmuPharma, as we continue to strengthen and progress our recently expanded development pipeline to value inflexion points, including Lupuzor™ and the partnership with  Avion Pharmaceuticals, as we prepare for the start of a new international optimised Phase III trial, in lupus patients”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Immupharma Plc

    More articles like this

    Immupharma Plc

    Pregnancy outcomes greatly improved in lupus patients

    Historically, pregnancy in patients with systemic lupus erythematosus (SLE) was considered so risky that physicians counseled women to avoid becoming pregnant and recommended that women carrying a child terminate their pregnancy. Now, a new study published

    Immupharma Plc

    Immupharma PLC Subscription to raise £2.66 million

    Commenting, ImmuPharma’s Chairman, Tim McCarthy, said: “We are delighted to be welcoming back Lanstead as a significant shareholder of the Company. Lanstead has been very supportive of the Company since their first investment in 2016 and

    Immupharma Plc

    10 Surprising Autoimmune Disease Facts You Need to Know

    If it seems like everyone and her grandma knows someone with an autoimmune disease, that’s because the term is a giant bucket that holds some 80 conditions, some as well-known as multiple sclerosis or type 1 diabetes, and as

    Immupharma Plc

    Autoimmune Diseases That Are Different For Women Than Men

    Research is just starting to explore how different conditions affect female-bodied people differently to male-bodied people. One of these areas in particular is in autoimmune conditions, where the immune system treats healthy tissues and cells as

    Immupharma Plc

    Why Autoimmune Diseases Cause the Body to Attack Itself

    A new study published in the journal Cell explores the cellular “runaway train” that allows lupus and other autoimmune diseases to spread throughout the body. Autoimmune disease is exactly what it sounds like—the body mistakenly fighting

    Immupharma Plc

    Chairman Q&A with Tim McCarthy at ImmuPharma PLC (LON:IMM)

    ImmuPharma’s Tim McCarthy discusses their final results, spend going forward, corporate strategy for Lupuzor, Nucant & Ureka, key milestones for shareholders and the initiation note issued by The Life Sciences Division in this exclusive interview with DirectorsTalk

    Immupharma Plc

    World Lupus Day: new report reveals need for care improvements

    The initiative is in collaboration with a Global Multidisciplinary Steering Committee, and the report outlines three specific, patient-centred Calls to Action to the lupus community. The report urges that we need increased awareness of lupus amongst